{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:36:48Z","timestamp":1791895008764,"version":"4.3.4"},"reference-count":106,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Graves\u2019 disease (GD) is an autoimmune entity that had an unchanged treatment paradigm for more than half a century with radioactive iodine, antithyroid drugs (ATDs), and surgery representing the mainstay of therapy, with variation in their use over time and geographic location. Hypothyroidism has been an accepted tradeoff in many cases, though recently there are increased concerns about altered quality of life in these patients. Fortunately, the last decade has seen an intense pursuit of GD's immunological mechanisms and a recalibration of classic treatment modalities focusing on thyroid preservation, as reflected in the preference for ATD as primary therapy, including its use in long-term protocols. The immune targets currently explored aim to address this gap by intervening in the TRAb lifecycle: minimizing production (eg, B-cell targeting), enhancing clearance (eg, neonatal Fc receptor inhibitors), or neutralizing its target\u2014the TSH receptor (eg, receptor blockade). While these approaches are going through the necessary clinical trials evaluation, we are starting to see the potential for technology and artificial intelligence to make an impact on how we identify, treat, and monitor patients with GD. The combination of these approaches will likely lead to a significant individualization of GD management that will take us from the goal of normalization of thyroid levels to that of inducing long-term remission and prevention of the associated autoimmune phenomena that GD is associated with. While time is needed for these aspects to mature, the future looks bright for our GD patients and maybe soon these lessons will open new doors for our patients with Hashimoto's thyroiditis as well.<\/jats:p>","DOI":"10.1210\/clinem\/dgag010","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:18:13Z","timestamp":1768220293000},"page":"1212-1224","source":"Crossref","is-referenced-by-count":5,"title":["Graves\u2019 disease: a new era of pathophysiology-guided therapeutics"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-8125","authenticated-orcid":false,"given":"Marius N","family":"Stan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Nutrition and Metabolism, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-4144","authenticated-orcid":false,"given":"David","family":"Toro-Tobon","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Nutrition and Metabolism, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"1","key":"2026042119583595300_dgag010-B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beem.2009.08.013","article-title":"Iodine intake as a determinant of thyroid disorders in populations","volume":"24","author":"Laurberg","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5441","key":"2026042119583595300_dgag010-B2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/bmj.1.5441.1015","article-title":"Pathogenesis of the hyperthyroidism of Graves's disease","volume":"1","author":"Adams","year":"1965","journal-title":"Br Med J"},{"issue":"1","key":"2026042119583595300_dgag010-B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026042119583595300_dgag010-B4","volume-title":"Endotext","author":"Toro-Tobon","year":"2000"},{"issue":"5","key":"2026042119583595300_dgag010-B5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","article-title":"Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003\u20132005","volume":"78","author":"Nystr\u00f6m","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026042119583595300_dgag010-B6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12020-017-1306-5","article-title":"Epidemiology, management and outcomes of Graves\u2019 disease-real life data","volume":"56","author":"Hussain","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"2026042119583595300_dgag010-B7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-08-0573","article-title":"Age and stress as determinants of the severity of hyperthyroidism caused by Graves\u2019 disease in newly diagnosed patients","volume":"160","author":"Vos","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026042119583595300_dgag010-B8","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1210\/jc.2009-2495","article-title":"Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study","volume":"95","author":"Boelaert","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119583595300_dgag010-B9","first-page":"930","article-title":"Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts","volume":"86","author":"Brix","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119583595300_dgag010-B10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","article-title":"Immunogenetics of autoimmune thyroid diseases: a comprehensive review","volume":"64","author":"Lee","year":"2015","journal-title":"J Autoimmun"},{"issue":"10","key":"2026042119583595300_dgag010-B11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"2026042119583595300_dgag010-B12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves\u2019 disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"issue":"11","key":"2026042119583595300_dgag010-B13","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 international survey of clinical practice patterns in the management of Graves\u2019 disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042119583595300_dgag010-B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.14374","article-title":"Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves\u2019 disease: a review of the literature","volume":"95","author":"El Kawkgi","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026042119583595300_dgag010-B15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40618-021-01730-1","article-title":"Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves\u2019 disease: a systematic scoping review","volume":"45","author":"Azizi","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026042119583595300_dgag010-B16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/EJE-16-0725","article-title":"Can we predict relapse in Graves\u2019 disease? Results from a systematic review and meta-analysis","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2026042119583595300_dgag010-B17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eprac.2024.12.011","article-title":"A predictive model for Graves\u2019 disease recurrence after antithyroid drug therapy: a retrospective multicenter cohort study","volume":"31","author":"El Kawkgi","year":"2024","journal-title":"Endocr Pract"},{"issue":"4","key":"2026042119583595300_dgag010-B18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves\u2019 disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026042119583595300_dgag010-B19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026042119583595300_dgag010-B20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119583595300_dgag010-B21","doi-asserted-by":"crossref","first-page":"1551983","DOI":"10.3389\/fendo.2025.1551983","article-title":"Integrating shear wave elastography into clinical prediction of Graves\u2019 disease recurrence: a novel risk scoring system","volume":"16","author":"Zha","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042119583595300_dgag010-B22","doi-asserted-by":"crossref","first-page":"756560","DOI":"10.3389\/fcell.2021.756560","article-title":"Identification of lncRNA and mRNA expression profile in relapsed Graves\u2019 disease","volume":"9","author":"Yao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026042119583595300_dgag010-B23","doi-asserted-by":"crossref","first-page":"761077","DOI":"10.3389\/fendo.2021.761077","article-title":"Recurrence of Graves\u2019 disease: what genetics of HLA and PTPN22 can tell us","volume":"12","author":"Vejrazkova","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026042119583595300_dgag010-B24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/thy.2000.10.891","article-title":"Remission of Graves\u2019 hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment","volume":"10","author":"Takasu","year":"2000","journal-title":"Thyroid"},{"issue":"2","key":"2026042119583595300_dgag010-B25","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1210\/clinem\/dgaf433","article-title":"Impact of minimal dose strategy before anti-thyroid drug discontinuation on relapse risk in Graves\u2019 disease","volume":"111","author":"Miyamura","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026042119583595300_dgag010-B26","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1210\/clinem\/dgae456","article-title":"Approach to the patient considering long-term antithyroid drug therapy for Graves\u2019 disease","volume":"109","author":"Azizi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026042119583595300_dgag010-B27","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"9","key":"2026042119583595300_dgag010-B28","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1210\/jc.2004-0247","article-title":"Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial","volume":"89","author":"Bonnema","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119583595300_dgag010-B29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/thy.2022.0514","article-title":"Incidence of and risk factors for neonatal hypothyroidism among women with Graves\u2019 disease treated with antithyroid drugs until delivery","volume":"33","author":"Yoshihara","year":"2023","journal-title":"Thyroid"},{"issue":"7","key":"2026042119583595300_dgag010-B30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ24-0434","article-title":"Prediction of fetal Graves\u2019 disease among pregnant women with Graves\u2019 disease who have undergone thyroidectomy or radioactive iodine therapy: a retrospective observational study","volume":"72","author":"Hosoda","year":"2025","journal-title":"Endocr J"},{"issue":"10","key":"2026042119583595300_dgag010-B31","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Tr\u00e4isk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026042119583595300_dgag010-B32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026042119583595300_dgag010-B33","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026042119583595300_dgag010-B34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00000658-199809000-00005","article-title":"The importance of surgeon experience for clinical and economic outcomes from thyroidectomy","volume":"228","author":"Sosa","year":"1998","journal-title":"Ann Surg"},{"issue":"2","key":"2026042119583595300_dgag010-B35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2012.04365.x","article-title":"Hepatotoxicity and cutaneous reactions after antithyroid drug administration","volume":"77","author":"Otsuka","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"30","key":"2026042119583595300_dgag010-B36","doi-asserted-by":"crossref","first-page":"e26707","DOI":"10.1097\/MD.0000000000026707","article-title":"The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism: a meta-analysis of randomized controlled trials","volume":"100","author":"Tan","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2026042119583595300_dgag010-B37","doi-asserted-by":"crossref","first-page":"e238655","DOI":"10.1001\/jamanetworkopen.2023.8655","article-title":"Comparison of propylthiouracil vs methimazole for thyroid storm in critically ill patients","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026042119583595300_dgag010-B38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/cen.12949","article-title":"Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm","volume":"84","author":"Isozaki","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119583595300_dgag010-B39","doi-asserted-by":"crossref","first-page":"e0286097","DOI":"10.1371\/journal.pone.0286097","article-title":"Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: a systematic review and meta-analysis","volume":"18","author":"Liu","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"2026042119583595300_dgag010-B40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1172\/JCI107744","article-title":"Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents","volume":"54","author":"Abuid","year":"1974","journal-title":"J Clin Invest"},{"issue":"2","key":"2026042119583595300_dgag010-B41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/clinem\/dgae472","article-title":"Effects of low-dose methotrexate with methimazole in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"110","author":"Xie","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119583595300_dgag010-B42","doi-asserted-by":"crossref","first-page":"1168936","DOI":"10.3389\/fendo.2023.1168936","article-title":"Azathioprine as an adjuvant therapy in severe Graves\u2019 disease: a randomized controlled open-label clinical trial","volume":"14","author":"Allam","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026042119583595300_dgag010-B43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab-exploratory trial in young people with Graves\u2019 disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119583595300_dgag010-B44","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"Fassi D","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119583595300_dgag010-B45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2265.1986.tb01674.x","article-title":"Effect of the anti-thyroid drug methimazole on interleukin-1 and interleukin-2 levels in vitro","volume":"25","author":"Weetman","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119583595300_dgag010-B46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0026-895X(24)12506-0","article-title":"Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging","volume":"60","author":"Kim","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"4","key":"2026042119583595300_dgag010-B47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/thy.1996.6.267","article-title":"Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves\u2019 thyroid tissues xenografted into severe combined immunodeficient (SCID) mice","volume":"6","author":"Resetkova","year":"1996","journal-title":"Thyroid"},{"issue":"3","key":"2026042119583595300_dgag010-B48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2567.1997.00421.x","article-title":"Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction","volume":"90","author":"Carayanniotis","year":"1997","journal-title":"Immunology"},{"issue":"3","key":"2026042119583595300_dgag010-B49","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026042119583595300_dgag010-B50","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1507\/endocrj.52.471","article-title":"A C\/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves\u2019 disease in Japanese","volume":"52","author":"Mukai","year":"2005","journal-title":"Endocr J"},{"issue":"7","key":"2026042119583595300_dgag010-B51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/1050725041517039","article-title":"Role of the CD40 locus in Graves\u2019 disease","volume":"14","author":"Houston","year":"2004","journal-title":"Thyroid"},{"key":"2026042119583595300_dgag010-B52","doi-asserted-by":"crossref","first-page":"691781","DOI":"10.3389\/fendo.2021.691781","article-title":"Precision medicine in Graves\u2019 disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody","volume":"12","author":"Faustino","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"27","key":"2026042119583595300_dgag010-B53","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026042119583595300_dgag010-B54","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"2026042119583595300_dgag010-B55","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology"},{"issue":"7","key":"2026042119583595300_dgag010-B56","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"issue":"7","key":"2026042119583595300_dgag010-B57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"S1","key":"2026042119583595300_dgag010-B58","article-title":"Efficacy and safety of the FcRn inhibitor, batoclimab, in Graves\u2019 thyroidal and extrathyroidal disease: a proof-of-concept study","volume":"34","author":"Kahaly","year":"2024","journal-title":"Thyroid"},{"issue":"12","key":"2026042119583595300_dgag010-B59","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"S1","key":"2026042119583595300_dgag010-B60","article-title":"Targeting the autoimmune etiology of Graves\u2019 disease: BHV-1300, a small molecule degrader, demonstrates deep and rapid reductions of IgG in humans","volume":"35","author":"Awsare","year":"2025","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"2026042119583595300_dgag010-B61","article-title":"OR31-05 specific and deep depletion of anti-TSHR autoantibodies for the treatment of Graves\u2019 and thyroid eye disease","volume":"9","author":"Gutierrez","year":"2025","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026042119583595300_dgag010-B62","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026042119583595300_dgag010-B63","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026042119583595300_dgag010-B64","first-page":"1597","article-title":"Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves\u2019 disease, and Graves\u2019 ophthalmopathy","volume":"31","author":"Ryder","year":"2021","journal-title":"Thyroid"},{"issue":"8","key":"2026042119583595300_dgag010-B65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1507\/endocrj.EJ25-0043","article-title":"Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70(TM) in Japanese Graves\u2019 disease patients: results of a phase 1 trial","volume":"72","author":"Noh","year":"2025","journal-title":"Endocr J"},{"issue":"1","key":"2026042119583595300_dgag010-B66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves\u2019 orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"2026042119583595300_dgag010-B67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"2026042119583595300_dgag010-B68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fendo.2016.00130","article-title":"TSH receptor signaling abrogation by a novel small molecule","volume":"7","author":"Latif","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042119583595300_dgag010-B69","doi-asserted-by":"crossref","first-page":"117258","DOI":"10.1016\/j.bmc.2023.117258","article-title":"Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist","volume":"84","author":"Karstens WFJ","year":"2023","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"2026042119583595300_dgag010-B70","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf037","article-title":"Inhibition of TSH receptor expression by a cyclotriazadisulfonamide as a potential treatment of Graves hyperthyroidism","volume":"166","author":"Krieger","year":"2025","journal-title":"Endocrinology"},{"issue":"8","key":"2026042119583595300_dgag010-B71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1089\/thy.2024.0177","article-title":"The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves\u2019 disease: a prospective study","volume":"34","author":"Fung","year":"2024","journal-title":"Thyroid"},{"issue":"1","key":"2026042119583595300_dgag010-B72","doi-asserted-by":"crossref","first-page":"2424903","DOI":"10.1080\/02656736.2024.2424903","article-title":"Ultrasound-guided percutaneous microwave ablation of primary hyperthyroidism: security and efficacy analysis","volume":"41","author":"Zhu","year":"2024","journal-title":"Int J Hyperthermia"},{"issue":"12","key":"2026042119583595300_dgag010-B73","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1007\/s00330-019-06303-8","article-title":"Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves\u2019 disease","volume":"29","author":"Lang","year":"2019","journal-title":"Eur Radiol"},{"key":"2026042119583595300_dgag010-B74","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/wjs.70035","article-title":"Comparing the health-related quality of life at two years after successful treatment of relapsed Graves\u2019 disease with radiofrequency ablation, surgery, or radioiodine","volume":"49","author":"Fung","year":"2025","journal-title":"World J Surg"},{"issue":"3","key":"2026042119583595300_dgag010-B75","article-title":"Hyperthyroidism due to Graves\u2019 disease after radiofrequency ablation","volume":"1","author":"McAninch","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"1","key":"2026042119583595300_dgag010-B76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12902-024-01824-w","article-title":"Graves\u2019 disease diagnosed nearly six months after microwave ablation of benign thyroid nodules: a case report","volume":"25","author":"Gu","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"2026042119583595300_dgag010-B77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2017.07.001","article-title":"The microbiota and autoimmunity: their role in thyroid autoimmune diseases","volume":"183","author":"K\u00f6hling","year":"2017","journal-title":"Clin Immunol"},{"issue":"Suppl 1","key":"2026042119583595300_dgag010-B78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000512255","article-title":"Microbiome and Graves\u2019 orbitopathy","volume":"9","author":"Masetti","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2026042119583595300_dgag010-B79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40168-018-0478-4","article-title":"Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease","volume":"6","author":"Masetti","year":"2018","journal-title":"Microbiome"},{"issue":"1","key":"2026042119583595300_dgag010-B80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00952-4","article-title":"Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha","year":"2021","journal-title":"Microbiome"},{"issue":"8","key":"2026042119583595300_dgag010-B81","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1210\/clinem\/dgad030","article-title":"Gut microbiome associated with Graves\u2019 disease and Graves orbitopathy: the INDIGO Multicenter European Study","volume":"108","author":"Biscarini","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026042119583595300_dgag010-B82","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40618-019-1010-9","article-title":"Alterations in the intestinal microbiota of patients with severe and active Graves\u2019 orbitopathy: a cross-sectional study","volume":"42","author":"Shi","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026042119583595300_dgag010-B83","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1089\/thy.2020.0193","article-title":"Gut microbiota may play a significant role in the pathogenesis of Graves\u2019 disease","volume":"31","author":"Jiang","year":"2021","journal-title":"Thyroid"},{"issue":"8","key":"2026042119583595300_dgag010-B84","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/thy.2023.0132","article-title":"Artificial intelligence in thyroidology: a narrative review of the current applications, associated challenges, and future directions","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"issue":"1","key":"2026042119583595300_dgag010-B85","doi-asserted-by":"crossref","first-page":"21096","DOI":"10.1038\/s41598-023-48199-x","article-title":"A machine learning-assisted system to predict thyrotoxicosis using patients\u2019 heart rate monitoring data: a retrospective cohort study","volume":"13","author":"Shin","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"2026042119583595300_dgag010-B86","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.2196\/mhealth.9884","article-title":"Clinical feasibility of monitoring resting heart rate using a wearable activity tracker in patients with thyrotoxicosis: prospective longitudinal observational study","volume":"6","author":"Lee","year":"2018","journal-title":"JMIR Mhealth Uhealth"},{"issue":"11","key":"2026042119583595300_dgag010-B87","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1210\/clinem\/dgae254","article-title":"Deep learning analysis with gray scale and Doppler ultrasonography images to differentiate Graves\u2019 disease","volume":"109","author":"Baek","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119583595300_dgag010-B88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2362.2004.01318.x","article-title":"Use of an artificial neural network to predict Graves\u2019 disease outcome within 2 years of drug withdrawal","volume":"34","author":"Orunesu","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"2026042119583595300_dgag010-B89","doi-asserted-by":"crossref","first-page":"1356055","DOI":"10.3389\/fendo.2024.1356055","article-title":"Advances in artificial intelligence in thyroid-associated ophthalmopathy","volume":"15","author":"Yi","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026042119583595300_dgag010-B90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.survophthal.2025.07.008","article-title":"Artificial intelligence in thyroid eye disease imaging: a systematic review","volume":"71","author":"Zhang","year":"2026","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"2026042119583595300_dgag010-B91","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"2026042119583595300_dgag010-B92","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2026042119583595300_dgag010-B93","doi-asserted-by":"crossref","first-page":"101383","DOI":"10.1016\/j.beem.2020.101383","article-title":"Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy","volume":"34","author":"Smith","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026042119583595300_dgag010-B94","first-page":"21-0201","article-title":"Thyroid dermopathy responds to teprotumumab therapy","volume":"2022","author":"Crespo-Trevino","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"12","key":"2026042119583595300_dgag010-B95","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1210\/clinem\/dgaa555","article-title":"Maternal thyroid dysfunction during pregnancy and the risk of adverse outcomes in the offspring: a systematic review and meta-analysis","volume":"105","author":"Ge","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119583595300_dgag010-B96","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/jcm12051811","article-title":"Management of hyperthyroidism during pregnancy: a systematic literature review","volume":"12","author":"Petca","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"2026042119583595300_dgag010-B97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid"},{"issue":"3","key":"2026042119583595300_dgag010-B98","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/jpc.16343","article-title":"Thyroid function and long-term outcomes of children born to mothers with Graves\u2019 disease: a 20-year review","volume":"59","author":"Sakornyutthadej","year":"2023","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"2026042119583595300_dgag010-B99","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1210\/clinem\/dgab747","article-title":"Fetal and neonatal thyroid dysfunction","volume":"107","author":"L\u00e9ger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026042119583595300_dgag010-B100","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s40618-022-01762-1","article-title":"An update on thyroid disorders in the postpartum period","volume":"45","author":"Peng","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026042119583595300_dgag010-B101","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/cen.13176","article-title":"Antithyroid drugs during breastfeeding","volume":"85","author":"Hudzik","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026042119583595300_dgag010-B102","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2026042119583595300_dgag010-B103","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/thy.2011.0334","article-title":"Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys","volume":"22","author":"Akamizu","year":"2012","journal-title":"Thyroid"},{"issue":"1","key":"2026042119583595300_dgag010-B104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CCM.0000000000004078","article-title":"Thyroid storm in the ICU: a retrospective multicenter study","volume":"48","author":"Bourcier","year":"2020","journal-title":"Crit Care Med"},{"issue":"12","key":"2026042119583595300_dgag010-B105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.EJ16-0336","article-title":"2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition)","volume":"63","author":"Satoh","year":"2016","journal-title":"Endocr J"},{"issue":"6","key":"2026042119583595300_dgag010-B106","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/1744-9987.13639","article-title":"Preoperative plasmapheresis in patients with Graves\u2019 disease intolerant to antithyroid drugs","volume":"25","author":"Apaydin","year":"2021","journal-title":"Ther Apher Dial"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag010\/66405223\/dgag010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1212\/66405223\/dgag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1212\/66405223\/dgag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:58:56Z","timestamp":1776815936000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/1212\/8425027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag010","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,13]]}}}